Roughly 32 million Americans have osteoarthritis, and knee osteoarthritis is the most common site. The majority also have obesity or overweight. Until this weekend in Washington, the drug industry’s answer to that overlap was a scale. Eli Lilly’s answer is now also a pain score.
At ObesityWeek 2026, Lilly presented Phase 3 data showing retatrutide, its investigational triple agonist targeting GIP, GLP-1, and glucagon receptors, reduced knee osteoarthritis pain by up to an average of 4.5 points (75.8%) at 68 weeks in the TRIUMPH-4 trial, as measured by the WOMAC pain subscale. In TRIUMPH-1-OA, a knee osteoarthritis subset within TRIUMPH-1, retatrutide reduced WOMAC pain by 3.22 points (4 mg), 3.48 points (9 mg), and 3.64 points (12 mg) at 80 weeks using the hybrid-treatment estimand. Lilly has also said more than 1 out of 8 retatrutide-treated patients in TRIUMPH-4 were completely free from knee pain at the end of the trial.
That is not a rounding error. It is a reframing. When a drug cuts pain by roughly three-quarters in a Phase 3 registrational trial and shows sustained pain improvements in a second Phase 3 program, it no longer belongs only in the obesity coverage conversation. It lands in orthopedics, rheumatology, and, critically, in the payer question that has shadowed the entire GLP-1 class.
Retatrutide’s triple-agonist profile targets weight, type 2 diabetes control, and obesity-related conditions such as sleep apnea and knee osteoarthritis in one therapy, which could appeal to payers and health systems looking at total disease burden across specialties. That framing matters because payers who have resisted covering obesity drugs on cost grounds face a different calculus when the same molecule is also a meaningful pain treatment in the indication. Orthopedic procedures are expensive. So is chronic NSAID use.
The sleep apnea numbers reinforce the same logic. Phase 3 results in TRIUMPH-1’s obstructive sleep apnea subset showed retatrutide reduced the apnea-hypopnea index by about 32 to 34 events per hour at 80 weeks on the 9 mg and 12 mg doses, with Lilly describing the higher-dose reduction as about 60.6%. TRIUMPH-2 includes a subset of patients with obstructive sleep apnea, but Lilly has not reported a Phase 3 apnea-hypopnea index reduction figure for TRIUMPH-2 in its public topline disclosures. OSA has its own specialist channel, its own insurer logic, and its own untreated-disease cost burden.
EloraTZP, the combination of eloralintide and tirzepatide, added another data point to the weekend’s conference slate. Phase 2 results showed participants with obesity or overweight and type 2 diabetes lost up to an average of 54.1 pounds at 48 weeks, with A1C dropping by up to an average of 2.9 percentage points. Phase 3 trials for EloraTZP are set to begin in Q4 2026, according to Lilly. Those numbers are Phase 2, with everything that implies about survivorship and population selection. But they set the floor for what Phase 3 will need to validate.
The bull case is that retatrutide arrives in 2027 with multiple FDA-eligible indications in a single weekly injection. Lilly has said it expects to file for retatrutide in the U.S. for obesity, obstructive sleep apnea, and knee osteoarthritis pain in Q1 2027. The filing pathway still has an open wrinkle because the FDA has classified retatrutide as a drug rather than a biologic, and Lilly has challenged that classification in court.
The bear case is that multi-indication launches are complex, pricing negotiations get harder when payers see the same molecule chasing multiple budget lines, and the competitive field is not standing still. Amgen’s MariTide is in Phase 3, including programs studying monthly and longer-interval dosing. Novo Nordisk has said a U.S. FDA decision on CagriSema is expected in Q4 2026. Neither has retatrutide’s knee osteoarthritis pain data, but both are closer to the market.
The number to watch next is TRIUMPH-5. The head-to-head trial versus tirzepatide lists an estimated primary completion of November 2026, with no topline readout date yet announced. That dataset will tell investors whether retatrutide can take share from Lilly’s own Zepbound, or whether the two drugs carve out distinct patient populations. The answer determines how big the retatrutide commercial opportunity actually is, and whether the pain-and-sleep expansion is additive revenue or cannibalization wearing a new label.
